Clinical trial

A Study of MOv18 IgE in Patients With Solid Tumours That Express Folate Receptor Alpha

NCT06547840

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention MOv18 IgE Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

A Study of MOv18 IgE in Patients With Solid Tumours That Express Folate Receptor Alpha

Design: INTERVENTIONAL · Status: RECRUITING · Phase: PHASE1

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2024-09-03

PhasePHASE1

Conditions

Advanced Ovarian Cancerunresolved

Platinum-resistant Ovarian Cancerunresolved

Triple Negative Breast Cancer (TNBC)unresolved

Triple -Negative Breast Cancercandidate · MONDO: triple-negative breast carcinoma

Endometrial Cancerverified · MONDO: endometrial cancer

Advanced Endometrial Cancerunresolved

Interventions

MOv18 IgEDRUG

Sponsors & collaborators

Epsilogen Ltdlead sponsor

Mapped research locations

LondonUnited Kingdom3 EdinburghUnited Kingdom1 LeedsUnited Kingdom1 BristolUnited Kingdom1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06547840 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.